Federation des caisses Desjardins du Quebec Acquires 13,261 Shares of Edwards Lifesciences Corporation $EW

Key Points

• Federation des caisses Desjardins du Quebec increased its stake in Edwards Lifesciences Corporation by 6.3%, acquiring an additional 13,261 shares during the first quarter, bringing its total holdings to 224,843 shares valued at approximately $16.3 million.
• Edwards Lifesciences reported a quarterly earnings of $0.67 EPS, surpassing analyst expectations, with revenue reaching $1.53 billion, marking an 11.9% year-over-year increase.
• Multiple research firms have upgraded their ratings and price targets for Edwards Lifesciences, with Deutsche Bank and Barclays increasing their targets to between $94.00 and $95.00, reflecting a positive outlook from analysts.

Federation des caisses Desjardins du Quebec grew its stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 6.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 224,843 shares of the medical research company's stock after purchasing an additional 13,261 shares during the quarter. Federation des caisses Desjardins du Quebec's holdings in Edwards Lifesciences were worth $16,298,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vega Investment Solutions acquired a new stake in Edwards Lifesciences during the fourth quarter worth approximately $27,000. Quantbot Technologies LP acquired a new stake in Edwards Lifesciences during the first quarter worth approximately $26,000. SouthState Corp acquired a new stake in Edwards Lifesciences during the first quarter worth approximately $27,000. Rossby Financial LCC acquired a new stake in Edwards Lifesciences during the first quarter worth approximately $29,000. Finally, Costello Asset Management INC acquired a new stake in Edwards Lifesciences during the first quarter worth approximately $29,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the sale, the insider directly owned 206,900 shares of the company's stock, valued at $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Daniel J. Lippis sold 4,114 shares of the firm's stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares in the company, valued at $1,748,278.92. This trade represents a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 22,014 shares of company stock worth $1,698,844. Corporate insiders own 1.29% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on EW shares. William Blair raised shares of Edwards Lifesciences to a "strong-buy" rating in a report on Friday, July 25th. Morgan Stanley lifted their target price on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company an "equal weight" rating in a report on Tuesday, July 15th. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Edwards Lifesciences from $85.00 to $94.00 and gave the company a "buy" rating in a report on Friday, July 25th. The Goldman Sachs Group reaffirmed a "buy" rating on shares of Edwards Lifesciences in a report on Friday, July 25th. Finally, Stifel Nicolaus lifted their price objective on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a "buy" rating in a research report on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $85.90.

Edwards Lifesciences Trading Down 0.1%

Shares of NYSE EW traded down $0.07 on Friday, reaching $80.89. 2,283,330 shares of the company traded hands, compared to its average volume of 3,558,037. Edwards Lifesciences Corporation has a fifty-two week low of $64.00 and a fifty-two week high of $83.00. The company has a 50 day moving average of $78.77 and a 200 day moving average of $75.21. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $47.49 billion, a PE ratio of 11.64, a P/E/G ratio of 3.90 and a beta of 1.07.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business had revenue of $1.53 billion during the quarter, compared to analysts' expectations of $1.49 billion. During the same quarter in the previous year, the business earned $0.70 EPS. The company's revenue for the quarter was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, equities research analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.